A multicenter analysis of prognostic factors for patients undergoing re-irradiation for recurrent glioblastoma

Clicks: 18
ID: 326892
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #66 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Re-irradiation (re-RT) has gained popularity in the treatment of recurrent or progressive glioblastoma (rGBM) after first-line treatment. However, uncertainties regarding optimal treatment dose, fraction size and target volume definition remain. In this multicenter analysis of the Western German Cancer Center (WTZ), we analyze prognostic factors for patients treated with re-RT for rGBM with different fraction regimens. Methods We analyzed patients with rGBM (CNS-WHO °4, IDH-wildtype) who received re-RT after standard first-line treatment (±salvage resection/chemotherapy) between 01/2010 and 12/2021. Clinical, histopathological, and radiological data were evaluated to identify prognostic factors influencing event-free and overall survival, as well as treatment tolerability. Results We identified 118 patients of whom 87 received normofractionated (1.8-2 Gy/fx) re-RT with a mean dose of 40.8 Gy using a mean GTV-PTV margin of 8.8 mm. 31 patients were treated with moderate hypofractionation (2.4-3.5 Gy/fx) up to a mean dose of 36 Gy with a mean GTV-PTV margin of 4.1 mm. Propensity score weighting was used to compensate prognostic factors between these two cohorts. Re-resection classification (no, STR, GTR, p < 0.0001), age at diagnosis (p = 0.0082), unifocal vs. multifocal progression (p = 0.021) and time between first and second RT (p = 0.0109) were identified as significant prognostic factors using stepwise parameter selection. The propensity score weighted survival was 8.8 months for normofractionation and 9.9 months for hypofractionation (p = 0.63). Conclusion Age at initial diagnosis, progression pattern and time between first and second RT are prognostic for patients undergoing re-irradiation. No significant survival difference between normofractionated and hypofractionated approaches was detected, which should be further investigated.
Reference Key
openalex_W7204988254 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Niklas Benedikt Pepper, Maja Guberina, Christoph Pöttgen, Fabian M. Troschel, Michael Oertel, Gerrit Fischedick, Lars Oliver Kiwitt, Cornelius Deuschl, Ramazan Jabbarli, Ulrich Sure, Philipp Dammann, K. F. Wrede, Sied Kebir, Andreas Junker, Michael Müther, Björn Scheffler, Oliver Grauer, Tanja Kuhlmann, Walter Stummer, Florian Padeberg, Hans Theodor Eich, Martin Stuschke, Nika Guberina
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag231
URL
https://doi.org/10.1093/noajnl/vdag231
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.